IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $39
Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $66
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45
Truist Securities Reiterates Buy on IDEAYA Biosciences, Lowers Price Target to $57
Guggenheim Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $52
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $63
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
IDEAYA Biosciences Q3 EPS $(1.22) Misses $(1.18) Estimate, Sales $10.242M Beat $6.857M Estimate
Is IDEAYA Biosciences (IDYA) A Bargain Following Its ESMO 2026 Clinical Data?
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress
William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating
IDEAYA Biosciences (IDYA) Rethinks Its R And D Leadership As Undervaluation Questions Grow
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.